
COCH Stock Forecast & Price Target
COCH Analyst Ratings
Bulls say
Envoy Medical is attractive because its fully implanted Acclaim cochlear implant has shown encouraging clinical momentum, with 12-month CNC word recognition improving to 53.2% from 39.2% at six months and 15.2% pre-implantation in the first 10 Stage 1 patients, while 9 of 10 showed a positive hearing response and no protocol-defined serious adverse events were reported. The pivotal study is advancing on schedule, with all 56 patients past three-month follow-up, the first three 12-month endpoint visits completed, and two of four PMA modules already submitted under the rolling review process. Despite modest revenue of $66K in 3Q26 and a $5.2M net loss, the company’s differentiated fully implanted design could expand cochlear implant adoption by addressing unmet need and eliminating externally worn components.
Bears say
Envoy Medical is facing a fragile liquidity position, with cash falling from $19.7M at the end of June 2026 to $14.6M at the end of September 2026 while operating cash outflows remained heavy at $(5.5M) in 2Q26 and $(5.0M) in 3Q26. The business appears reliant on external financing or warrant exercises, since outstanding Series A-1 and Series A-2 warrants could generate up to $48M of gross proceeds, yet the company may still need additional capital within the next 12 months absent those exercises. Its negative outlook is further reinforced by 7.7M Class A shares and 2.7M pre-funded warrants outstanding as of November 5, 2026, plus the risk of failing to regain NASDAQ minimum bid-price compliance by November 16, 2026.
This aggregate rating is based on analysts' research of Envoy Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
COCH Analyst Forecast & Price Prediction
Start investing in COCH
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Envoy Medical Inc (COCH) Forecast
COCH Analyst Forecast & Price Prediction
Start investing in COCH
Order type
Buy in
Order amount
Est. shares
0 shares